Yuhui Yao
Overview
Explore the profile of Yuhui Yao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
51
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wei G, Fan L, Song X, Zhou W, Sun M, Sun Y, et al.
Discov Oncol
. 2025 Feb;
16(1):187.
PMID: 39954036
Background: Almonertinib is a third-generation EGFR-TKI, and studies on its resistance mechanisms are lacking. Cancer-associated fibroblasts (CAFs) can influence resistance to targeted therapeutics, but their role and mechanism of action...
2.
Kong J, Zou Y, Huang Y, Yao Y, Gan Q, Chen Z, et al.
Technol Cancer Res Treat
. 2024 Oct;
23:15330338241284845.
PMID: 39380441
Background: The intricate task of diagnosing and managing small renal masses (SRMs) has become progressively convoluted within the realm of clinical practice. Contemporary clinical prediction instruments may succumb to a...
3.
Peng C, Li X, Yao Y, Nie Y, Fan L, Zhu C
Cancer Biol Ther
. 2024 Jul;
25(1):2373497.
PMID: 38967961
Despite advances in targeted therapies, primary and acquired resistance make the treatment of colorectal cancer (CRC) a pressing issue to be resolved. According to reports, the development of CRC is...
4.
Jia Y, Yao Y, Fan L, Huang Q, Wei G, Shen P, et al.
J Nanobiotechnology
. 2024 Jun;
22(1):346.
PMID: 38898493
Chemoresistance remains a significant challenge for effective breast cancer treatment which leads to cancer recurrence. CRISPR-directed gene editing becomes a powerful tool to reduce chemoresistance by reprogramming the tumor microenvironment....
5.
Huang Y, Chen L, Zou Y, Yu H, Xie W, Gan Q, et al.
Heliyon
. 2024 Jun;
10(11):e31587.
PMID: 38841471
Aims: To provide a comprehensive bibliometric overview of drug resistance in bladder cancer (BC) from 1999 to 2022, aiming to illuminate its historical progression and guide future investigative avenues. Methods:...
6.
Gao F, Wu Y, Wang R, Yao Y, Liu Y, Fan L, et al.
Acta Pharm Sin B
. 2024 Jun;
14(6):2685-2697.
PMID: 38828153
Targeting androgen receptor (AR) has shown great therapeutic potential in triple-negative breast cancer (TNBC), yet its efficacy remains unsatisfactory. Here, we aimed to identify promising targeted agents that synergize with...
7.
Yao Y, Cui M, Meng G
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
. 2024 May;
40(4):354-361.
PMID: 38710518
Objective To prepare a monoclonal antibody (mAb) against mouse NOD-like receptor family pyrin domain-containing 3 (NLRP3) and assess its specificity. Methods A gene fragment encoding mouse NLRP3 exon3 (Ms-N3) was...
8.
Huang Y, Liu L, Gan Q, Shen Z, Yao Y, Liao C, et al.
Heliyon
. 2024 Apr;
10(7):e28160.
PMID: 38571632
Background: The prognostic significance of tumor size with adrenocortical carcinoma (ACC) patients has not yet been thoroughly evaluated. Our objective was to investigate the influence of tumor size on prognostic...
9.
Lai K, Sun D, Dai R, Samoro R, Park H, Astrand A, et al.
Respir Med
. 2024 Apr;
:107611.
PMID: 38570145
Background: Benralizumab is indicated as add-on therapy in patients with uncontrolled, severe eosinophilic asthma; it has not yet been evaluated in a large Asian population with asthma in a clinical...
10.
Huang Y, Liao C, Shen Z, Zou Y, Xie W, Gan Q, et al.
Front Immunol
. 2024 Mar;
15:1297542.
PMID: 38444854
Background: Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) remains the cornerstone of treatment for muscle-invasive bladder cancer (MIBC). While platinum-based regimens have demonstrated benefits in tumor downstaging and improved...